Windsor Clinical Research

This systematic review evaluates the effectiveness of various neuroprotective strategies in enhancing recovery following acute ischemic stroke, focusing on interventions such as normobaric oxygen (NBO), lithium, selective serotonin reuptake inhibitors (SSRIs), and Cerebrolysin. Drawing upon data from six primary studies, including randomized controlled trials (RCTs) and meta-analyses, we assessed these therapies' impact on functional outcomes, motor recovery, and neurological improvement. Normobaric oxygen, across 12 RCTs, demonstrated limited efficacy in improving recovery outcomes or reducing mortality. Lithium, supported by animal models but with inconclusive human data, showed potential in reducing stroke volume but did not significantly enhance functional recovery in clinical trials. SSRIs, particularly fluoxetine, showed moderate success in improving motor recovery, as evidenced by the FLAME (Fluoxetine for Motor Recovery after Acute Ischaemic Stroke) trial and meta-analyses. Cerebrolysin demonstrated consistent improvement in early neurological function and motor recovery, with a number-needed-to-treat (NNT) of 7.1 for early NIHSS (National Institutes of Health Stroke Scale) score improvements. Our Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided search covered PubMed, Medline, Embase, and the Cochrane Library up to September 2024. These findings emphasize the mixed efficacy of these neuroprotective interventions and underscore the necessity for personalized treatment protocols and further large-scale, controlled trials to clarify their roles in clinical practice. This review contributes to the ongoing dialogue on optimizing post-stroke recovery and highlights the critical need for evidence-based neuroprotective strategies.

Rosacea is a chronic inflammatory skin condition associated with erythema, inflammation and skin sensitivity. To assess the benefit of a dermocosmetic cream (DC cream) containing Sphingobioma xenophaga extract and soothing agent in adult females with rosacea-associated erythema and sensitive skin. During phase 1, DC was applied twice daily on the randomized half-face and compared to usual-skincare (USC) for 28 days. During phase 2, DC was applied on the full face twice daily for 56 days. Clinical, instrumental and skin sensitivity assessments were performed at all visits; demodex density (standardized skin surface biopsy (SSSB) method) was performed at baseline and D28, quality of life (QoL) was assessed using the stigmatization questionnaire (SQ), Rosacea Quality of Life index (ROSAQoL) and Dermatology Life Quality Index (DLQI) at baseline and D84. At D28, a significant benefit of DC over USC was observed for erythema, tightness, burning and stinging (all p≤0.05), erythema measured by chromameter (p<0.01), corneometry and transepidermal water loss (p<0.0001 and p<0.05, respectively), skin sensitivity (p<0.001) and significant reduction of mean demodex density (p<0.05) on the DC side. At D84, DC significantly (all p<0.05) improved clinical signs and symptoms on both sides of the face compared to baseline; SQ, ROSAQoL and DLQI scores improved by 40.4%, 25.0% and 55.7%, respectively compared to baseline. Tolerance was excellent. DC significantly improved erythema, skin sensitivity, demodex count, QoL and feeling of stigmatization of subjects with rosacea and is very well tolerated.

Advances in Bioengineering and Biomedical Science Research, list of open access journals, open access, open access journals, open access publication, open access publisher, open access publishing, open access journal articles, Opast Publishing Group, Articles in Press

This study proposes the integration of conversational AI in community-based survey platforms to generate personalized narratives for vulnerable patients such as the elderly, those with palliative care needs, or from diverse language communities. The study emphasizes the capabilities of AI-driven analysis and proposes the use of this technology to analyze health survey data and produce personalized narratives that address the specific needs of each individual. The proposed approach aims to enhance patient engagement by providing compassionate assistance and insightful guidance derived directly from the survey responses.

<b>Background:</b> While digital therapeutics offer a potential to address Global Initiative for Asthma (GINA)-identified factors for poor asthma outcomes (misdiagnosis, poor control, suboptimal adherence, incorrect inhaler technique, trigger exposures, overuse of short-acting β-agonist and no action plan), the availability of multiple apps adds complexity, limiting their usability. Herein, we studied the Breathe Digital Ecosystem, an integrated platform with multiple features, which is currently authorised for investigational testing in Canada (Fig 1A). <b>Methods:</b> In this ongoing mixed-methods study (NCT05594654) in patients at GINA Step 3–5, the daily usage of Breathe app was analysed using both the in-app algorithm and manually for 2 months. Qualitative data were also collected. <b>Results:</b> Of 17/30 patients who participated at the time of analysis, 57±15% of participants used the Breathe app daily. In total, 48±13% of the users captured their medication completions daily (Breezhaler assistant: 37±14%; manually: 11±10%). Qualitative feedback demonstrated its user-friendliness along with patients’ satisfaction with different features including the electronic respiratory educator, medication alert and chatbot instructions (Fig 1B). <b>Conclusions:</b> These preliminary results showed that Breathe app was accepted, used and positively reviewed by patients. Future analysis will determine its potential in controlling GINA-identified gaps.